The identification of this autocrine pro-tumorigenic action of CXCL8 is of great relevance, because it clearly indicates that targeting the CXCL8–CXCR1 circuit could produce therapeutic benefits, at least in patients bearing an aggressive radioiodine-refractory thyroid cancer (135). Here, CXCL8 is linked to thyroid gland carcinoma.